293 related articles for article (PubMed ID: 29106676)
1. Safety and efficacy of taurolidine/urokinase versus taurolidine/heparin as a tunneled catheter lock solution in hemodialysis patients: a prospective, randomized, controlled study.
Al-Ali F; Hamdy AF; Hamad A; Elsayed M; Zafar Iqbal Z; Elsayed A; Ibrahim R; Tolba H; Buanan H; Fawzy A
Nephrol Dial Transplant; 2018 Apr; 33(4):619-626. PubMed ID: 29106676
[TBL] [Abstract][Full Text] [Related]
2. Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters.
Winnicki W; Herkner H; Lorenz M; Handisurya A; Kikić Ž; Bielesz B; Schairer B; Reiter T; Eskandary F; Sunder-Plassmann G; Sengoelge G
Kidney Int; 2018 Mar; 93(3):753-760. PubMed ID: 28890326
[TBL] [Abstract][Full Text] [Related]
3. Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).
Gudiol C; Nicolae S; Royo-Cebrecos C; Aguilar-Guisado M; Montero I; Martín-Gandul C; Perayre M; Berbel D; Encuentra M; Arnan M; Cisneros-Herreros JM; Carratalà J
Trials; 2018 May; 19(1):264. PubMed ID: 29720244
[TBL] [Abstract][Full Text] [Related]
4. Prevention of tunneled cuffed catheter dysfunction with prophylactic use of a taurolidine urokinase lock: A randomized double-blind trial.
Bonkain F; Stolear JC; Catalano C; Vandervelde D; Treille S; Couttenye MM; Dhondt A; Libertalis M; Allamani M; Madhoun P; Van Craenenbroeck AH; Vanommeslaeghe F; Van Hulle F; Durieux P; Van Limberghen I; Tielemans C; Wissing KM
PLoS One; 2021; 16(5):e0251793. PubMed ID: 34015014
[TBL] [Abstract][Full Text] [Related]
5. Cefazolin-gentamicin versus taurolidine-citrate for the prevention of infection in tunneled central catheters in hemodialysis patients: A quasi-experimental trial.
Bueloni TNV; Marchi D; Caetano C; de Souza Cavalcante R; Mendes Amaral ML; Ponce D
Int J Infect Dis; 2019 Aug; 85():16-21. PubMed ID: 31102823
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-containing locking solution in the prevention of dialysis catheter dysfunction: a double blind randomized controlled trial.
Bonkain F; Van Hulle F; Janssens P; Catalano C; Allamani M; Stolear JC; Vandervelde D; Libertalis M; Treille S; Couttenye MM; Dhondt A; Van Biesen W; Fils JF; Tielemans C; Wissing KM
J Vasc Access; 2017 Sep; 18(5):436-442. PubMed ID: 28623638
[TBL] [Abstract][Full Text] [Related]
7. Impact of locking solutions on conditioning biofilm formation in tunnelled haemodialysis catheters and inflammatory response activation.
Jiménez Hernández M; Soriano A; Filella X; Calvo M; Coll E; Rebled JM; Poch E; Graterol F; Compte MT; Maduell F; Fontsere N
J Vasc Access; 2021 May; 22(3):370-379. PubMed ID: 32691665
[TBL] [Abstract][Full Text] [Related]
8. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution.
Betjes MG; van Agteren M
Nephrol Dial Transplant; 2004 Jun; 19(6):1546-51. PubMed ID: 14993498
[TBL] [Abstract][Full Text] [Related]
9. A Taurolidine-Citrate-Heparin Lock Solution Effectively Eradicates Pathogens From the Catheter Biofilm in Hemodialysis Patients.
Zwiech R; Adelt M; Chrul S
Am J Ther; 2016; 23(2):e363-8. PubMed ID: 23665885
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Double-Blind, Placebo-Controlled Trial (TAURCAT Study) of Citrate Lock Solution for Prevention of Endoluminal Central Venous Catheter Infection in Neutropenic Hematological Patients.
Gudiol C; Arnan M; Aguilar-Guisado M; Royo-Cebrecos C; Sánchez-Ortega I; Montero I; Martín-Gandul C; Laporte-Amargós J; Albasanz-Puig A; Nicolae S; Perayre M; Berbel D; Tebe C; Riera J; Sureda A; Cisneros JM; Carratalà J
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712211
[TBL] [Abstract][Full Text] [Related]
11. A 2% taurolidine catheter lock solution prevents catheter-related bloodstream infection (CRBSI) and catheter dysfunction in hemodialysis patients.
Neusser MA; Bobe I; Hammermeister A; Wittmann U
Br J Nurs; 2021 Jul; 30(14):S24-S32. PubMed ID: 34288746
[TBL] [Abstract][Full Text] [Related]
12. Citrate versus heparin lock for hemodialysis catheters: a systematic review and meta-analysis of randomized controlled trials.
Zhao Y; Li Z; Zhang L; Yang J; Yang Y; Tang Y; Fu P
Am J Kidney Dis; 2014 Mar; 63(3):479-90. PubMed ID: 24125729
[TBL] [Abstract][Full Text] [Related]
13. Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients.
Reidenberg BE; Wanner C; Polsky B; Castanheira M; Shelip A; Stalleicken D; Pfaffle AE
Eur J Clin Microbiol Infect Dis; 2018 Apr; 37(4):661-663. PubMed ID: 29214504
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies.
Dümichen MJ; Seeger K; Lode HN; Kühl JS; Ebell W; Degenhardt P; Singer M; Geffers C; Querfeld U
J Hosp Infect; 2012 Apr; 80(4):304-9. PubMed ID: 22342714
[TBL] [Abstract][Full Text] [Related]
15. Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin.
Handrup MM; Møller JK; Schrøder H
Pediatr Blood Cancer; 2013 Aug; 60(8):1292-8. PubMed ID: 23417891
[TBL] [Abstract][Full Text] [Related]
16. Taurolidine-citrate-heparin lock reduces catheter-related bloodstream infections in intestinal failure patients dependent on home parenteral support: a randomized, placebo-controlled trial.
Tribler S; Brandt CF; Petersen AH; Petersen JH; Fuglsang KA; Staun M; Broebech P; Moser CE; Jeppesen PB
Am J Clin Nutr; 2017 Sep; 106(3):839-848. PubMed ID: 28793993
[No Abstract] [Full Text] [Related]
17. Taurolidine-citrate-heparin catheter lock solution reduces staphylococcal bacteraemia rates in haemodialysis patients.
Murray EC; Deighan C; Geddes C; Thomson PC
QJM; 2014 Dec; 107(12):995-1000. PubMed ID: 24939191
[TBL] [Abstract][Full Text] [Related]
18. Taurolidine/Citrate Lock Therapy for Primary Prevention of Catheter-Related Infections in Cancer Patients: Results of a Prospective, Randomized, Phase IV Trial (ATAPAC).
Longo R; Llorens M; Goetz C; Platini C; Eid N; Sellies J; Ouamara N; Quétin P
Oncology; 2017; 93(2):99-105. PubMed ID: 28463827
[TBL] [Abstract][Full Text] [Related]
19. Effect of taurolidine citrate and unfractionated heparin on inflammatory state and dialysis adequacy in hemodialysis patients.
Ezzat H; Elsharkawy M; Rezk K; Mohsen R; Mansour A; Emara A
J Vasc Access; 2023 Jan; 24(1):45-51. PubMed ID: 34112001
[TBL] [Abstract][Full Text] [Related]
20. Biofilm formation in long-term central venous catheters in children with cancer: a randomized controlled open-labelled trial of taurolidine versus heparin.
Handrup MM; Fuursted K; Funch P; Møller JK; Schrøder H
APMIS; 2012 Oct; 120(10):794-801. PubMed ID: 22958287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
